E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension.

ABSTRACT: Risk stratification is an essential tool in the management of pulmonary arterial hypertension (PAH). These tools lack detailed echocardiographic assessment which plays a central role in clinical risk assessment in PAH. Thus, we aimed at assessing whether adding echocardiography-driven data to REVEAL Lite 2.0 (Registry to Evaluate Early and Long-Term PAH Disease Management) improves the assessment of risk stratification in PAH. A retrospective analysis of 134 consecutive patients between January 2016 and December 2019 was done. We identified patients who experienced a disease progression "event" defined by the initiation of intravenous (IV) or parenteral prostacyclin, transplant referral, or death due to PAH. All other PAH patients who did not experience an "event" during this period were i

SUBMITTER: Sahay S 

PROVIDER: S-EPMC9052981 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature